Home > Healthcare > Drug Device Combination > Drug Filled Devices > U.S. Hormone Replacement Therapy Market

U.S. Hormone Replacement Therapy Market Share

Report ID: GMI7407
Published Date: Nov 2023
Report Format: PDF

Download Free Sample

U.S. Hormone Replacement Therapy Market Share

The key industry players operating in this market have established themselves through top-notch quality products, advanced technology, and a strong market presence. Novo Nordisk A/S, Pfizer, Inc., and Eli Lilly & Company are prominent leaders in this market. These significant players offer a wide range of solutions for hormonal imbalances and disorders. They are consistently involved in creating new opportunities in the healthcare sector.

Market players operating in the U.S. hormone replacement therapy industry is as mentioned below:

Eli Lilly and Company
Bayer AG
Pfizer Inc.
Viatris, Inc.
Noven Pharmaceuticals, Inc.
Merck KGaA
Novo Nordisk A/S
F. Hoffmann-La Roche Ltd.
ASCEND Therapeutics US, LLC.
Abbott Laboratories
Teva Pharmaceutical Industries Ltd.
Novartis AG

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

U.S. hormone replacement therapy industry size was USD 6.9 billion in 2022 and is anticipated to be valued at USD 13.4 billion from 2023-2032 due to the aging population and the significant number of women reaching menopausal stages.

The oral route of administration recorded 43.5% share of the market in 2022 driven by non-invasive nature, precise and consistent drug dosing, affordability, and the strong preference of patients.

The hospital pharmacies distribution channel segment held 57.2% of the U.S. hormone replacement therapy market share in 2022 due to the presence of the highest quality of care.

Some of the major hormone replacement therapy firms in the U.S. include Eli Lilly and Company, Bayer AG, Pfizer Inc., Viatris, Inc., Noven Pharmaceuticals, Inc., Merck KGaA, Novo Nordisk A/S, and F. Hoffmann-La Roche Ltd.